200 related articles for article (PubMed ID: 15738744)
1. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine.
Thase ME; Tran PV; Wiltse C; Pangallo BA; Mallinckrodt C; Detke MJ
J Clin Psychopharmacol; 2005 Apr; 25(2):132-40. PubMed ID: 15738744
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.
Wernicke J; Lledó A; Raskin J; Kajdasz DK; Wang F
Drug Saf; 2007; 30(5):437-55. PubMed ID: 17472422
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor.
Sharma A; Goldberg MJ; Cerimele BJ
J Clin Pharmacol; 2000 Feb; 40(2):161-7. PubMed ID: 10664922
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder.
Thase ME; Pritchett YL; Ossanna MJ; Swindle RW; Xu J; Detke MJ
J Clin Psychopharmacol; 2007 Dec; 27(6):672-6. PubMed ID: 18004135
[TBL] [Abstract][Full Text] [Related]
5. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
Goldstein DJ; Mallinckrodt C; Lu Y; Demitrack MA
J Clin Psychiatry; 2002 Mar; 63(3):225-31. PubMed ID: 11926722
[TBL] [Abstract][Full Text] [Related]
6. Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine.
Hirschfeld RM; Vornik LA
J Clin Psychiatry; 2004; 65 Suppl 4():46-52. PubMed ID: 15046541
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects.
Turcotte JE; Debonnel G; de Montigny C; Hébert C; Blier P
Neuropsychopharmacology; 2001 May; 24(5):511-21. PubMed ID: 11282251
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder.
Hunziker ME; Suehs BT; Bettinger TL; Crismon ML
Clin Ther; 2005 Aug; 27(8):1126-43. PubMed ID: 16199241
[TBL] [Abstract][Full Text] [Related]
10. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study.
Chalon SA; Granier LA; Vandenhende FR; Bieck PR; Bymaster FP; Joliat MJ; Hirth C; Potter WZ
Neuropsychopharmacology; 2003 Sep; 28(9):1685-93. PubMed ID: 12784100
[TBL] [Abstract][Full Text] [Related]
11. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence.
van Kerrebroeck P; Abrams P; Lange R; Slack M; Wyndaele JJ; Yalcin I; Bump RC;
BJOG; 2004 Mar; 111(3):249-57. PubMed ID: 14961887
[TBL] [Abstract][Full Text] [Related]
12. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder.
Delgado PL; Brannan SK; Mallinckrodt CH; Tran PV; McNamara RK; Wang F; Watkin JG; Detke MJ
J Clin Psychiatry; 2005 Jun; 66(6):686-92. PubMed ID: 15960560
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study.
Raskin J; Wang F; Pritchett YL; Goldstein DJ
Pain Med; 2006; 7(5):373-85. PubMed ID: 17014595
[TBL] [Abstract][Full Text] [Related]
14. Duloxetine: a dual reuptake inhibitor.
Dugan SE; Fuller MA
Ann Pharmacother; 2004 Dec; 38(12):2078-85. PubMed ID: 15522980
[TBL] [Abstract][Full Text] [Related]
15. Effect of chronic administration of duloxetine on serotonin and norepinephrine transporter binding sites in rat brain.
Gould GG; Javors MA; Frazer A
Biol Psychiatry; 2007 Jan; 61(2):210-5. PubMed ID: 16650830
[TBL] [Abstract][Full Text] [Related]
16. The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate.
Derby MA; Zhang L; Chappell JC; Gonzales CR; Callaghan JT; Leibowitz M; Ereshefsky L; Hoelscher D; Leese PT; Mitchell MI
J Cardiovasc Pharmacol; 2007 Jun; 49(6):384-93. PubMed ID: 17577103
[TBL] [Abstract][Full Text] [Related]
17. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Perahia DG; Wang F; Mallinckrodt CH; Walker DJ; Detke MJ
Eur Psychiatry; 2006 Sep; 21(6):367-78. PubMed ID: 16697153
[TBL] [Abstract][Full Text] [Related]
18. Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram).
Mallinckrodt CH; Prakash A; Houston JP; Swindle R; Detke MJ; Fava M
Neuropsychobiology; 2007; 56(2-3):73-85. PubMed ID: 18037817
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine.
Goldstein DJ; Lu Y; Detke MJ; Wiltse C; Mallinckrodt C; Demitrack MA
J Clin Psychopharmacol; 2004 Aug; 24(4):389-99. PubMed ID: 15232330
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine for the treatment of major depressive disorder in older patients.
Nelson JC; Wohlreich MM; Mallinckrodt CH; Detke MJ; Watkin JG; Kennedy JS
Am J Geriatr Psychiatry; 2005 Mar; 13(3):227-35. PubMed ID: 15728754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]